Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rein Therapeutics ( (RNTX) ) has provided an update.
On November 3, 2025, Rein Therapeutics announced that the FDA has lifted the clinical hold on their Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, allowing the company to resume U.S. enrollment in late 2025 or early 2026. This clearance is a significant milestone for Rein, as early data suggests LTI-03 may not only slow fibrosis but also promote lung healing, potentially impacting the treatment landscape for IPF. The trial will be conducted across approximately 20 U.S. sites and is part of a broader global study, with initial topline data expected in Q3 2026.
The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications. Their lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibition of profibrotic signaling, with Orphan Drug Designation in the U.S.
Average Trading Volume: 159,472
Technical Sentiment Signal: Sell
Current Market Cap: $36.85M
For an in-depth examination of RNTX stock, go to TipRanks’ Overview page.